TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18821668
Drug: Calcium (1,000
Normalized name: calcium carbonate 390 mg calcium (1,000 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1,000 mg/day)
Study: 18821668
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 plus Calcium (1,000 mg/day)
Study: 15774435
Drug: Bobath based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bobath based treatment (BB)
Study: 15774435
Drug: Movement science
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Movement science based treatment (MSB)
Study: 12444814
Drug: Venlafaxine (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (225 to 350 mg/day)
Study: 12444814
Drug: Clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (150 to 225 mg/day)
Study: 10343140
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron saccharate for 8 weeks
Study: 10343140
Drug: Erythropoietin in
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin in patients without response after iron treatment
Study: 1935353
Drug: Levo-praziquantel (L-PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levo-praziquantel (L-PZQ) at 20 mg/kg
Study: 1935353
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) at 40 mg/kg
Study: 6460467
Drug: Tetrabenazine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrabenazine (maximum dosage of 200 mg per day for three or more weeks)
Study: 30488957
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AT and RESP
Study: 23373268
Drug: High-dose albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose albumin group
Study: 23373268
Drug: High-dose diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose diuretic group
Study: 20429825
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5% lidocaine medicated plaster and pregabalin
Study: 12045777
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine 15 mg daily
Study: 12045777
Drug: Oral mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mesalamine 800 mg tid
Study: 2217349
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg per day (first 10 days)
Study: 2217349
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three tablets per day for one week)
Study: 2217349
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in the morning, noon, or evening (subsequent weeks)
Study: 2217349
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (after 10 years of treatment)
Study: 28875459
Drug: Fluticasone furoate/umeclidinium/vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/umeclidinium/vilanterol 100 µg/62.5 µg/25 µg
Study: 28875459
Drug: Budesonide/formoterol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 400 µg/12 µg
Study: 20440568
Drug: Methylphenidate (48-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (48-hour on-off medication protocol)
Study: 20440568
Drug: ADHD children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD children (on medication)
Study: 11350752
Drug: Antioxidants (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (500 mg of vitamin C and 400 mg of vitamin E)
Study: 9036201
Drug: chronotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: chronotherapy with heparin and curantyl added to traditional therapy
Study: 21878082
Drug: traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional therapy
Study: 6383790
Drug: Progabide (19.3‐36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progabide (19.3‐36 mg/kg/day)
Study: 27342914
Drug: Reduced-dose 2007
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose 2007 Southern Hemisphere trivalent inactivated influenza vaccine formulated with Advax™ delta inulin adjuvant (LTIV+Adj)
Study: 27342914
Drug: Full-dose standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose standard TIV vaccine (no adjuvant)
Study: 27342914
Drug: Reduced-dose TIV
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose TIV vaccine containing Advax adjuvant
Study: 27342914
Drug: Standard TIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TIV vaccine
Study: 24676998
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP) 25-150 mg eq. injected intramuscularly in deltoid muscle
Study: 24676998
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP) 25-150 mg eq. injected intramuscularly in gluteal muscle
Study: 22490266
Drug: Therapeutic assertive
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic assertive community treatment (ACT)
Study: 17400681
Drug: Bilevel positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilevel positive airway pressure (BPAP) for 3 months, daily use of 4.8 +/- 0.3 hours
Study: 15588555
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral Minocin MR (minocycline) once daily (o.d.)
Study: 15588555
Drug: Combined erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined erythromycin (2% erythromycin) and benzoyl peroxide (5% benzoyl peroxide) formulation
Study: 15588555
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral oxytetracycline (b.d.)
Study: 15588555
Drug: Topical Benzamycin
Normalized name: Benzamycin Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Benzamycin (3% erythromycin + 5% benzoyl peroxide)
Study: 15588555
Drug: Topical Panoxyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Panoxyl Aquagel (5% benzoyl peroxide)
Study: 15588555
Drug: Topical erythromycin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin-containing regimens
Study: 15588555
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (minocycline and oxytetracycline)
Study: 15588555
Drug: Topical treatments
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatments (particularly benzoyl peroxide)
Study: 15588555
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator group (topical Panoxyl Aquagel + oral placebo)
Study: 8550863
Drug: 25% tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% tetracycline HCl from poly(D,L-lactide/glycolide) film strips (25 TTC-PLGA)
Study: 2136818
Drug: GR32191 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 0.125 mg/kg
Study: 2136818
Drug: GR32191 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 0.25 mg/kg
Study: 2136818
Drug: GR32191 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 0.5 mg/kg
Study: 2136818
Drug: GR32191 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 1.0 mg/kg
Study: 2136818
Drug: GR32191 17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 17.5 mg, three times daily
Study: 2136818
Drug: GR32191 17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 17.5 mg, every 12 hours
Study: 30311402
Drug: Short-acting insulin
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting insulin (insulin lispro) at 30°C and 10% humidity
Study: 30311402
Drug: Short-acting insulin
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting insulin (insulin lispro) at 15°C and 10% humidity
Study: 14742390
Drug: Flurbiprofen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (1 mg/kg) under propofol anesthesia (PROP-F)
Study: 14742390
Drug: Flurbiprofen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (1 mg/kg) under isoflurane anesthesia (ISO-F)
Study: 14742390
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 mL/kg) under propofol anesthesia (PROP-S)
Study: 14742390
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 mL/kg) under isoflurane anesthesia (ISO-S)
Study: 31313068
Drug: Bortezomib at
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib at an intravenous dose of 1.3 mg/m2 twice weekly
Study: 27919632
Drug: MF59‐adjuvanted trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59‐adjuvanted trivalent inactivated influenza vaccine (MF59‐aTIV) + 13‐valent pneumococcal conjugate vaccine (PCV13)
Study: 27919632
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of MF59‐aTIV and PCV13
Study: 25099523
Drug: Pregabalin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75 mg twice-weekly)
Study: 24107437
Drug: Intravenous zoledronate
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronate
Study: 18192897
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli lipopolysaccharide (LPS) infusion
Study: 16729930
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 or 40 mg daily
Study: 11050702
Drug: Cibalginadue Fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibalginadue Fast (test formulation)
Study: 11050702
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (tablets)
Study: 6486124
Drug: Hydralazine 86
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 86 mg daily
Study: 6486124
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 to 90 mg)
Study: 15041084
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg sublingual testosterone
Study: 24176251
Drug: Immediate start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate start of the contraceptive patch (directly observed application of the patch in the clinic)
Study: 24176251
Drug: Delayed start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed start of the contraceptive patch (beginning the Sunday after their abortion)
Study: 18238972
Drug: Cessation medication
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cessation medication discussion with obstetric providers
Study: 18238972
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use during pregnancy
Study: 18238972
Drug: Medication discussion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication discussion at postpartum visit
Study: 18238972
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use postpartum
Study: 18238972
Drug: Factors associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors associated with medication use
Study: 16325968
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA supplementation (390-1170 mg/day)
Study: 12755236
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation (60 mg elemental iron, 300 mg ferrous sulphate, 400 microg folic acid, Monday to Friday)
Study: 12755236
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation (one tablet once a week every Monday)
Study: 12755236
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation
Study: 12755236
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation
Study: 10939035
Drug: Theophylline (Respicur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (Respicur retard 400 mg)
Study: 3080101
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin injection therapy (controls)
Study: 24651243
Drug: Medial cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial cord stimulation with 40 mL of 0.5% ropivacaine
Study: 24651243
Drug: Posterior cord
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior cord stimulation with 40 mL of 0.5% ropivacaine
Study: 20685858
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg alum-formulated human recombinant GAD65
Study: 7984577
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HLA-DR2 and haptoglobin phenotype 2-2
Study: 12947433
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 x 1 g) containing a natural carotenoid mixture (4 x 7.6 mg)
Study: 12947433
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 x 1 g)
Study: 9051365
Drug: Conventional subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subcutaneous injection technique (with skin preparation)
Study: 9051365
Drug: Experimental injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental injection technique through clothing
Study: 8398919
Drug: Longer radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Longer radiotherapy treatment schedule
Study: 8398919
Drug: Shorter radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shorter radiotherapy treatment schedule
Study: 3137773
Drug: Low-dose disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose disodium etidronate (EHDP) 5-7 mg/kg/day
Study: 3137773
Drug: Low-dose disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose disodium etidronate (EHDP) plus 1 alpha-hydroxyvitamin D3 (1 alpha D3) 0.5 mcg daily
Study: 20576011
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) administration
Study: 28885392
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of external thermomechanical stimulation and distraction
Study: 26979712
Drug: Coffee consumption
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee consumption (four 200 ml coffee beverages containing 160 mg caffeine)
Study: 25572571
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus cisplatin with concurrent thoracic radiation (SCCR)
Study: 25572571
Drug: Cisplatin alone
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin alone with concurrent thoracic radiation (CCR)
Study: 18821628
Drug: 0.5% midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% midazolam formulation (MDG) - 1.0 mg total dose, intranasally into each nostril
Study: 18821628
Drug: 1% midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% midazolam formulation (UDG) - 1.0 mg total dose, intranasally into one nostril
Study: 18821628
Drug: 1% midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% midazolam formulation (UDG)
Study: 18821628
Drug: 0.5% midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% midazolam formulation (MDG)
Study: 8899495
Drug: Short-course triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course triple therapy (bismuth subsalicylate two tablets four times daily, amoxicillin 1 g twice daily, metronidazole 500 mg four times daily)
Study: 8899495
Drug: High-dose omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omeprazole (40 mg twice a day) with amoxicillin (1 g twice a day)
Study: 1665778
Drug: Naloxone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.75 mg/70 kg i.m.)
Study: 1665778
Drug: Methadone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (30 mg i.m.)
Study: 30595323
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen (DR) atorvastatin therapy (10 mg for 12 weeks)
Study: 30595323
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other day regimen (EODR) atorvastatin therapy (10 mg for 12 weeks)
Study: 30595323
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen (DR) atorvastatin therapy
Study: 30595323
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other day regimen (EODR) atorvastatin therapy
Study: 25039318
Drug: Anakinra (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (150 mg daily for 4 weeks)
Study: 15755829
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (HP) - 5 g . kg(‐1) . d(‐1)
Study: 15755829
Drug: Intermediate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate protein intake (IP) - 3 g . kg(‐1) . d(‐1)
Study: 15755829
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein intake (NP) - 1.5 g . kg(‐1) . d(‐1)
Study: 14749241
Drug: Isoflavone supplement
Normalized name: Soyrel Soy Isoflavone Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplement (26 mg biochanin A, 16 mg formononetin, 1 mg genistein, 0.5 mg daidzein for 1 year)
Study: 14749241
Drug: Isoflavone supplement
Normalized name: Soyrel Soy Isoflavone Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplement
Study: 8348874
Drug: Ethanol (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.25, 0.5, 1.0 g/kg)
Study: 3522444
Drug: Calcitonin (CT)
DrugBank: Calcitonin porcine (DB13189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (CT) injection and placebo tablets
Study: 3522444
Drug: Phosphate (Pi)
DrugBank: Phosphate ion (DB14523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate (Pi) tablets and placebo injection
Study: 3522444
Drug: Calcitonin (CT)
DrugBank: Calcitonin porcine (DB13189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (CT) injection and phosphate tablets
Study: 3522444
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection and placebo tablets (Control group)
Study: 29518432
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement
Study: 24719064
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (TC: hydroquinone, tretinoin, and fluocinolone acetonide) treatment for 8 weeks followed by maintenance regimens (twice weekly or tapering regimen)
Study: 24719064
Drug: Tapering regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering regimen of TC
Study: 24719064
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly regimen of TC
Study: 23072083
Drug: Electroacupuncture neurostimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture neurostimulation therapy
Study: 18664995
Drug: Classroom-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom-based intervention and 17-session manual-based group therapy intervention (tier 2)
Study: 10102960
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, metronidazole 400 mg, and clarithromycin 250 mg (OMC)
Study: 10102960
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg (OAC)
Study: 10383498
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (O)
Study: 2129648
Drug: Algicon (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algicon (10 ml four times daily)
Study: 2129648
Drug: Gaviscon (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon (20 ml four times daily)
Study: 29723106
Drug: Catgut embedding
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catgut embedding treatment (n=45)
Study: 29723106
Drug: Sham catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham catgut embedding treatment (n=45)
Study: 23081768
Drug: LEARN Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEARN Program for Weight Management (lifestyle modification treatment)
Study: 18812659
Drug: lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacidipine 4 mg/d